Published in Br J Cancer on January 17, 2005
Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci (2007) 1.64
Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reprod Biol Endocrinol (2005) 1.36
Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res (2009) 1.06
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia (2006) 1.04
Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary. J Ovarian Res (2012) 1.02
The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J (2007) 0.96
An immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours. Br J Cancer (2008) 0.91
Ovarian cancer: involvement of the matrix metalloproteinases. Reproduction (2015) 0.88
Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells. PPAR Res (2008) 0.86
Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int (2015) 0.85
Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer. BMC Cancer (2006) 0.84
Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. PLoS One (2011) 0.84
To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. PPAR Res (2008) 0.83
Expression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma. J Clin Pathol (2006) 0.81
Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Cancer Res Clin Oncol (2011) 0.81
Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ. PLoS One (2014) 0.80
BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget (2015) 0.79
Significance of LRP and PPAR-gamma Expression in Lipomatous Soft Tissue Tumors. Open Orthop J (2010) 0.77
Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer. World J Biol Chem (2010) 0.77
Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma. BMC Cancer (2016) 0.75
Peroxisome proliferator activated receptor γ protein expression is asymmetrically distributed in primary lung tumor and metastatic to lung osteosarcoma samples and does not correlate with gene methylation. BMC Vet Res (2015) 0.75
Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy. Oncotarget (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
The mechanisms of action of PPARs. Annu Rev Med (2002) 6.71
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
Roles of PPARs in health and disease. Nature (2000) 5.87
Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol (2003) 5.87
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res (1999) 3.11
The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol (1998) 3.08
Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A (1999) 2.45
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 2.23
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol (2003) 2.22
Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics (2004) 2.15
Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A (2001) 2.06
Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer (2003) 1.86
Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol (2000) 1.83
Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol (2004) 1.74
Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem (2002) 1.48
Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer (2000) 1.47
Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab (2004) 1.44
Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer (2003) 1.44
Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res (2000) 1.30
Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res (2001) 1.25
Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia (2001) 1.18
Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab (2003) 1.17
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene (2003) 1.12
A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem (1996) 1.08
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J Biol Chem (2003) 1.08
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res (2000) 1.02
The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med (2003) 1.02
Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut (2004) 0.98
Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol (2002) 0.98
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene (2003) 0.97
Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer (2002) 0.96
Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2001) 0.94
Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res (2004) 0.93
Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat Res (2000) 0.91
Retracted Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res (2004) 0.89
Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest New Drugs (2002) 0.89
Expression and function of PPARgamma in rat placental development. Biochem Biophys Res Commun (2004) 0.86
HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin Cancer Res (2003) 0.86
Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res (2003) 0.86
The ovarian surface epithelium: simple source of a complex disease. Minerva Ginecol (2003) 0.82
Characterization of peroxisome proliferator-activated receptor alpha in normal rat mammary gland and 2-amino-l-methyl-6-phenylimidazo[4, 5-b]pyridine-induced mammary gland tumors from rats fed high and low fat diets. Toxicol Lett (2000) 0.81
PPARgamma expression in normal human placenta, hydatidiform mole and choriocarcinoma. Mol Hum Reprod (2002) 0.81
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 4.76
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum (2008) 4.25
Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 3.25
Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum (2006) 3.03
Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study. J Infect Dis (1988) 3.01
Fourier transform infrared (FTIR) spectral mapping of the cervical transformation zone, and dysplastic squamous epithelium. Gynecol Oncol (2004) 2.75
Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110. Science (1990) 2.69
Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 2.47
The Use of Intrathecal Heparin in Conjunction with Streptomycin in the Treatment of Tuberculous Meningitis: Preliminary Report. J Clin Pathol (1948) 2.40
The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG (2011) 2.32
Outcome of out-of-hospital cardiac or respiratory arrest in children. N Engl J Med (1996) 2.29
Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology (2011) 2.24
The IMAGEN study: reinforcement-related behaviour in normal brain function and psychopathology. Mol Psychiatry (2010) 2.23
The skeletal metastatic complications of renal cell carcinoma. Int J Oncol (2001) 2.12
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene (2007) 2.12
Prospective assessment of outcomes following disposable arthroscopy of the temporomandibular joint. Br J Oral Maxillofac Surg (2013) 2.09
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer (2008) 1.75
Temperature-sensitive cell division component in a mutant of Salmonella typhimurium. J Gen Microbiol (1971) 1.63
Induced expression of endothelial-leukocyte adhesion molecules in human cardiac allografts. Transplantation (1991) 1.62
Overexpression of Bcl-x(L) in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion. Am J Physiol Endocrinol Metab (2000) 1.62
Disappearing hyperdense middle cerebral artery sign in ischaemic stroke patients treated with intravenous thrombolysis: clinical course and prognostic significance. J Neurol Neurosurg Psychiatry (2008) 1.60
Epithelial neoplasms of the vermiform appendix (exclusive of carcinoid). I. Adenocarcinoma of the appendix. Cancer (1976) 1.58
Hospital policy on appropriate use of life-sustaining treatment. University of Toronto Joint Centre for Bioethics/Critical Care Medicine Program Task Force. Crit Care Med (2001) 1.57
Outcome of children with hematologic malignancy who are admitted to an intensive care unit. Crit Care Med (1988) 1.56
The prevalence of posttraumatic stress disorder and its clinical significance among Southeast Asian refugees. Am J Psychiatry (1990) 1.55
Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 1.54
Ageing of the human corneal stroma: structural and biochemical changes. Biochim Biophys Acta (1992) 1.52
Is there any value in bimanual pelvic examination as a screening test. Med J Aust (1995) 1.52
Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection (2004) 1.51
Gastric-outlet obstruction induced by prostaglandin therapy in neonates. N Engl J Med (1992) 1.47
Quantifying mosquito biting patterns on humans by DNA fingerprinting of bloodmeals. Am J Trop Med Hyg (2001) 1.44
Tampons: a novel patient-administered method for the assessment of genital human papillomavirus infection. J Infect Dis (1992) 1.44
Diagnostic MR imaging features of craniocerebral Aspergillosis of sino-nasal origin in immunocompetent patients. Acta Neurochir (Wien) (2005) 1.41
A method of administering topical anaesthesia for flexible airway endoscopy. Anaesthesia (2000) 1.40
Geographical incidence of oesophageal cancer in West Kenya. East Afr Med J (1966) 1.40
The anatomy of an OPTI: Part 2. The CORE system. Ohio Osteopathic Hospital Association. Ohio Association of Osteopathic Medical Directors. Ohio Osteopathic Association. J Am Osteopath Assoc (1997) 1.39
Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit (1993) 1.36
Ventilatory predictors of pulmonary hypoplasia in congenital diaphragmatic hernia, confirmed by morphologic assessment. J Pediatr (1987) 1.35
Epithelial neoplasms of the vermiform appendix (exclusive of carcinoid). II. Cystadenomas, papillary adenomas, and adenomatous polyps of the appendix. Cancer (1976) 1.34
Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci U S A (1990) 1.33
Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br J Cancer (2003) 1.31
Pairing and recombination at meiosis of Brassica rapa (AA) x Brassica napus (AACC) hybrids. Theor Appl Genet (2006) 1.29
The incidence of cancer of the oesophagus in West Kenya. Br J Cancer (1969) 1.29
Diversion colitis in patients with myelopathy: clinical, endoscopic, and histopathological findings. J Spinal Cord Med (2000) 1.29
Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis (2002) 1.27
Cloning and expression of the thrombospondin related adhesive protein gene of Plasmodium berghei. Mol Biochem Parasitol (1997) 1.27
Impact of household hygiene and water source on the prevalence and transmission of Helicobacter pylori: a South Indian perspective. Singapore Med J (2007) 1.27
Alcohol problems in acute male medical admissions. Health Bull (Edinb) (1976) 1.25
A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol (1986) 1.25
Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer. Br J Cancer (2004) 1.23
Identification of a gene cluster, czr, involved in cadmium and zinc resistance in Pseudomonas aeruginosa. Gene (1999) 1.21
The absence of genital human papillomavirus DNA in virginal women. Int J STD AIDS (1993) 1.20
Reappraisal of esophagogastrectomy for esophageal malignancy. Am J Surg (1979) 1.18
Congenital diaphragmatic hernia--a tale of two cities: the Toronto experience. J Pediatr Surg (1997) 1.17
The role of BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone development: effects on osteoblastic differentiation induced by parathyroid hormone and vitamin D(3). Stem Cells Dev (2004) 1.17
FTIR microspectroscopic study of cell types and potential confounding variables in screening for cervical malignancies. Biospectroscopy (1998) 1.16
Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis (2005) 1.16
Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans (2003) 1.15
Videokeratography database of normal human corneas. Br J Ophthalmol (1996) 1.15
Screening practice for familial adenomatous polyposis: the potential for regional registers. Br J Surg (1993) 1.14
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer (2005) 1.13
Identification of two strains of cultured canine renal epithelial cells (MDCK cells) which display entirely different physiological properties. Q J Exp Physiol (1981) 1.12
Evolution of VHL tumourigenesis in nerve root tissue. J Pathol (2006) 1.11
B16 melanoma cell arrest in the mouse liver induces nitric oxide release and sinusoidal cytotoxicity: a natural hepatic defense against metastasis. Cancer Res (2000) 1.10
Tumor cell surface alpha 4 beta 1 integrin mediates adhesion to vascular endothelium: demonstration of an interaction with the N-terminal domains of INCAM-110/VCAM-1. Cell Regul (1991) 1.10
Limitations of the clonal agar assay for the assessment of primary human ovarian tumour biopsies. Br J Cancer (1982) 1.10
Epitopes in the interacting regions of beta-dystroglycan (PPxY motif) and dystrophin (WW domain). Biochim Biophys Acta (2001) 1.10
New haemoglobin A1c: the way it is reported is about to change... Intern Med J (2007) 1.10
Hernia-sac cancer. Lancet (1969) 1.10
Detection of cervical intraepithelial neoplasia in vivo using confocal endomicroscopy. BJOG (2009) 1.09
Proteomic analysis of human plasma: failure of centrifugal ultrafiltration to remove albumin and other high molecular weight proteins. Proteomics (2001) 1.09
Altered placental oxidative stress status in gestational diabetes mellitus. Placenta (2004) 1.09
A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int J Tuberc Lung Dis (2003) 1.09
The contribution of spirituality and spiritual coping to anxiety and depression in women with a recent diagnosis of gynecological cancer. Int J Gynecol Cancer (2005) 1.08
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther (2011) 1.07
Self-expanding foam-filled tracheostomy tube cuffs and the management of airway emergencies. Anaesthesia (2013) 1.07
The impact of ultrasonography on diagnosis and management of patients with musculoskeletal conditions. Arthritis Rheum (2001) 1.06
The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood (2001) 1.06
Stop routine CD4 monitoring in HIV-infected patients with fully suppressed virus and CD4 >=350 cells/ml. Clin Infect Dis (2013) 1.05
Subclavian vein catheterization in the infant. J Pediatr Surg (1974) 1.05
Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer (2006) 1.04
The effect of vascular coiling on venous perfusion during experimental umbilical cord encirclement. Am J Obstet Gynecol (2001) 1.04
Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol (2010) 1.04
Lifestyle and biologic contributors to proximal femur bone mineral density and hip axis length in two distinct ethnic groups of premenopausal women. Osteoporos Int (1999) 1.03
Reduction of Cr(VI) and bioaccumulation of chromium by gram positive and gram negative microorganisms not previously exposed to Cr-stress. Environ Technol (2002) 1.02
Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 1.02
Thrombosis after central venous cannulation. Med J Aust (1976) 1.02
Progestogen treatment options for early endometrial cancer. BJOG (2010) 1.02
Effects of dietary phytoestrogens in postmenopausal women. Climacteric (1998) 1.02
Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. Diabet Med (2001) 1.01
Rotational delivery of the fetus: Kielland's forceps and two other methods compared. Br J Obstet Gynaecol (1982) 1.00